LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq: RGLS). Investors who purchased or otherwise acquired Regulus shares between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 2017 lead plaintiff motion deadline.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Regulus revealed that it was contacted by the U.S. Food and Drug Administration ("FDA") that its new drug against the chronic hepatitis C virus infection will be placed on clinical hold due to another incidence of jaundice.
On January 27, 2017, Regulus disclosed that the FDA would not remove the clinical hold on RG-101 until the agency confirms the last safety and efficacy information from continued clinical and pre-clinical studies.
When this information was revealed to the investing public, shares of Regulus fell sharply, causing investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.